Table 3.
All-cause mortality in 163 people with HIV developing a first CV event.
| Death (n) | MR per 1,000 PY | MRR (95% CI) | aMRR (95% CI) | |
|---|---|---|---|---|
| Total | 31 | 40.4 (28.4–57.4) | ||
| Gender | ||||
| Male | 23 | 36.0 (23.9–54.2) | Ref (1) | |
| Female | 8 | 62.1 (31.0–124.1) | 1.72 (0.77–3.85) | |
| Age at baseline | 1.06 (1.03–1.10) | 1.07 (1.03–1.11) | ||
| Route of HIV transmission | ||||
| MSM | 3 | 11.6 (3.7–35.9) | Ref (1) | Ref (1) |
| Heterosexual men | 11 | 49.4 (27.4–89.2) | 4.26 (1.19–15.28) | 2.90 (0.76–11.03) |
| Women | 5 | 74.5 (31.0–179.0) | 6.43 (1.54–26.91) | 5.89 (1.35–25.60) |
| IDU | 8 | 57.3 (28.7–114.6) | 4.95 (1.31–18.6) | 2.58 (0.52–12.72) |
| Unknown | 4 | 50.5 (19.0–134.5) | 4.36 (0.98–19.48) | 1.67 (0.30–9.19) |
| Cardiovascular disease | ||||
| Heart failure | 9 | 42.0 (21.8–80.6) | 2.13 (0.66–6.92) | |
| Ischemic heart disease | 4 | 19.7 (7.4–52.4) | Ref (1) | |
| Cerebrovascular disease | 14 | 56.2 (33.3–94.8) | 2.85 (0.94–8.67) | |
| Peripheral vascular disease | 4 | 39.8 (14.9–105.9) | 2.02 (0.50–8.08) | |
| Calendar time | ||||
| 2005–2009 | 1 | 120.8 (17.0–857.7) | 3.45 (0.46–25.58) | |
| 2010–2014 | 8 | 60.9 (30.4–121.7) | 1.74 (0.77–3.90) | |
| 2015–2021 | 22 | 35.0 (23.1–53.2) | Ref (1) | |
| AIDS at baseline | ||||
| Yes | 11 | 89.5 (49.6–161.6) | 2.88 (1.38–6.02) | |
| No | 20 | 31.0 (2.0–48.1) | Ref (1) | |
| CD4 cell count at ART initiation | ||||
| Late presenters, CD4 ≤ 350 cells/μL | 26 | 5.0 (34.0–73.4) | 2.48 (0.95–6.45) | 1.24 (0.45–3.44) |
| Non-late presenters, >350 cells/μL | 5 | 20.2 (8.4–48.5) | Ref (1) | Ref (1) |
| Comorbidity at ART initiation | ||||
| Diabetes mellitus | ||||
| Yes | 2 | 88.5 (22.1–354.0) | 2.27 (0.54–9.53) | |
| No | 29 | 38.9 (27.1–56.0) | Ref (1) | |
| Dyslipidaemia | ||||
| Yes | 3 | 60.2 (19.4–186.8) | 1.54 (0.47–5.08) | |
| No | 28 | 39.0 (26.9–56.5) | Ref (1) | |
| Arterial hypertension | ||||
| Yes | 3 | 41.5 (13.4–128.7) | 1.03 (0.31–3.39) | |
| No | 28 | 40.3 (27.8–58.3) | Ref (1) | |
| Chronic kidney disease | ||||
| Yes | 1 | 107.9 (15.2–756.8) | 2.73 (0.37–2.00) | |
| No | 30 | 39.6 (27.7–56.6) | Ref (1) | |
| Chronic lung disease | ||||
| Yes | 4 | 215.8 (81.0–575.0) | 5.99 (2.10–17.11) | 5.06 (1.61–15.91) |
| No | 27 | 36.0 (24.7–52.6) | Ref (1) | Ref (1) |
| Chronic liver disease | ||||
| Yes | 8 | 78.7 (39.3–157.3) | 2.28 (1.02–5.09) | 3.49 (1.08–11.26) |
| No | 23 | 34.5 (23.0–52.0) | Ref (1) | Ref (1) |
| Malignancy | ||||
| Yes | 3 | 77.4 (24.9–239.8) | 2.01 (0.61–6.62) | |
| No | 28 | 38.4 (26.5–55.6) | Ref (1) | |
| Depression | ||||
| Yes | 2 | 40.4 (28.1–58.2) | 0.99 (0.24–4.14) | |
| No | 29 | 39.9 (1.0–159.7) | Ref (1) | |
aMRR, adjusted mortality rate ratio; ART, antiretroviral therapy; IDU, injection drug use; MR, mortality rate; MRR, mortality rate ratio; MSM, men who have sex with men; PY, person-years.